Adam Hacker, PhD Joins Autolus as Senior Vice President for Regulatory Affairs and Quality

LONDON, Oct. 17, 2018 /PRNewswire/ -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Adam Hacker, PhD to the newly created position of senior vice president for Regulatory Affairs and Quality.

Dr. Christian Itin, Autolus' chairman and chief executive officer, commented: "Adam joins us at an exciting point in our growth cycle as we advance our clinical product candidates and transition additional programs to clinical stage. His proven track record of successfully navigating complex programs through global regulatory processes has him well prepared to help us drive our innovative, programmed T cell therapies to market."

Dr. Hacker joins Autolus after a decade at Janssen Pharmaceuticals, where he most recently served as vice president, Head of Vaccines and Scientific Innovation Projects, Global Regulatory Affairs. In this role, Dr. Hacker was responsible for leading regulatory activities across all scientific innovation projects, including collaborating with and overseeing efforts related to the Company's work on the Microbiome, Disease Interception, Regenerative Medicines & Advanced Therapeutics, and Clinical Trial Innovation/Digital Technology, among others. During his tenure at Janssen Pharmaceuticals, Dr. Hacker also oversaw all regulatory aspects of the Company's Ebola vaccine and therapeutic product development, as well as leading hematology and oncology therapeutic areas and regulatory and medical affairs functions for the Europe Middle East Africa (EMEA). Dr. Hacker honed his expertise in regulatory affairs in prior positions, including Head of Oncology, Immunology and Cardiovascular Therapeutic areas at Biogen Idec Ltd. and as Regulatory Advisor and Regulatory Project Manager at GE Healthcare and GlaxoSmithKline Pharmaceuticals, respectively.

He earned a PhD in developmental molecular biology from the National Institute of Medical Research, London and holds an undergraduate degree from Oxford University.

About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to: https://www.autolus.com

Forward-Looking Statement
This press release contains certain forward-looking statements regarding Autolus Therapeutics' research and development programs. These statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Autolus Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in the Company's registration statement on Form F-1 and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements. Autolus Therapeutics undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE Autolus Therapeutics plc